ALKMAlkame Holdings, Inc.
The schedule
- Mon16Nov
Estimated Q3 2026 earnings release, evaluating operating cash flow against a critically low $15k cash balance.
- Wed20Jan
High risk of further toxic equity issuance or convertible debt conversion necessary to service the company's $1.6M debt load.
- Thu15Apr
FY2026 earnings report assessing the viability of continued operations under severe capital constraints and potential delisting threats.
Past
- Wed8Jul
Actual outcome: Bull
ALKM's stock surged due to the potential FDA approval of its drug, which could significantly expand its market access and revenue potential. The approval would validate the drug's efficacy and safety, leading to increased commercialization efforts and investor confidence. [Market retrospective · Medium-Term (11–30 days)] Missed anticipation: +9900.0% from 2026-07-09 to 2026-09-07 (~12.6σ vs typical 30d vol). Target date 2026-08-15 reached; move through 2026-09-07 observed. Confidence 95%. [Market retrospective · Medium-Term (11–30 days)] Updated observation 2026-09-08: +9900.0% from 2026-07-09 (~12.6σ). Target date 2026-08-15 reached; move through 2026-09-08 observed. [Market retrospective · Medium-Term (11–30 days)] Updated observation 2026-09-08: +9900.0% from 2026-07-09 (~12.6σ). Target date 2026-08-15 reached; move through 2026-09-08 observed. [Market retrospective · Medium-Term (11–30 days)] Updated observation 2026-09-09: +9900.0% from 2026-07-09 (~12.6σ). Target date 2026-08-15 reached; move through 2026-09-09 observed. [Market retrospective · Medium-Term (11–30 days)] Updated observation 2026-09-10: +9900.0% from 2026-07-09 (~12.6σ). Target date 2026-08-15 reached; move through 2026-09-10 observed. [Market retrospective · Medium-Term (11–30 days)] Updated observation 2026-09-14: +9900.0% from 2026-07-09 (~12.6σ). Target date 2026-08-15 reached; move through 2026-09-14 observed.
ALKM's stock surged due to the potential FDA approval of its drug, which could significantly expand its market access and revenue potential. The approval would validate the drug's efficacy and safety, leading to increased commercialization efforts and investor confidence. [Market retrospective · Medium-Term (11–30 days)] Missed anticipation: +9900.0% from 2026-07-09 to 2026-09-07 (~12.6σ vs typical 30d vol). Target date 2026-08-15 reached; move through 2026-09-07 observed. Confidence 95%. [Market retrospective · Medium-Term (11–30 days)] Updated observation 2026-09-08: +9900.0% from 2026-07-09 (~12.6σ). Target date 2026-08-15 reached; move through 2026-09-08 observed. [Market retrospective · Medium-Term (11–30 days)] Updated observation 2026-09-08: +9900.0% from 2026-07-09 (~12.6σ). Target date 2026-08-15 reached; move through 2026-09-08 observed. [Market retrospective · Medium-Term (11–30 days)] Updated observation 2026-09-09: +9900.0% from 2026-07-09 (~12.6σ). Target date 2026-08-15 reached; move through 2026-09-09 observed. [Market retrospective · Medium-Term (11–30 days)] Updated observation 2026-09-10: +9900.0% from 2026-07-09 (~12.6σ). Target date 2026-08-15 reached; move through 2026-09-10 observed. [Market retrospective · Medium-Term (11–30 days)] Updated observation 2026-09-14: +9900.0% from 2026-07-09 (~12.6σ). Target date 2026-08-15 reached; move through 2026-09-14 observed.
